Literature DB >> 35543831

Myelodysplastic syndrome in an alemtuzumab-treated multiple sclerosis patient.

Jean Hee Kim1, Silvia Park2, Woojun Kim3.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35543831     DOI: 10.1007/s10072-022-06124-6

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.830


× No keyword cloud information.
  5 in total

Review 1.  Immune mechanisms of new therapeutic strategies in multiple sclerosis-A focus on alemtuzumab.

Authors:  Luisa Klotz; Sven G Meuth; Heinz Wiendl
Journal:  Clin Immunol       Date:  2011-04-15       Impact factor: 3.969

Review 2.  Lymphopenia and DMTs for relapsing forms of MS: Considerations for the treating neurologist.

Authors:  Edward J Fox; Guy J Buckle; Barry Singer; Vibhuti Singh; Aaron Boster
Journal:  Neurol Clin Pract       Date:  2019-02

3.  Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDS.

Authors:  A Kuendgen; M Nomdedeu; H Tuechler; G Garcia-Manero; R S Komrokji; M A Sekeres; M G Della Porta; M Cazzola; A E DeZern; G J Roboz; D P Steensma; A A Van de Loosdrecht; R F Schlenk; J Grau; X Calvo; S Blum; A Pereira; P Valent; D Costa; A Giagounidis; B Xicoy; H Döhner; U Platzbecker; C Pedro; M Lübbert; I Oiartzabal; M Díez-Campelo; M T Cedena; S Machherndl-Spandl; M López-Pavía; C D Baldus; M Martinez-de-Sola; R Stauder; B Merchan; A List; C Ganster; T Schroeder; M T Voso; M Pfeilstöcker; H Sill; B Hildebrandt; J Esteve; B Nomdedeu; F Cobo; R Haas; F Sole; U Germing; P L Greenberg; D Haase; G Sanz
Journal:  Leukemia       Date:  2020-06-29       Impact factor: 11.528

Review 4.  Alemtuzumab: a review of efficacy and risks in the treatment of relapsing remitting multiple sclerosis.

Authors:  Cristina Guarnera; Placido Bramanti; Emanuela Mazzon
Journal:  Ther Clin Risk Manag       Date:  2017-07-14       Impact factor: 2.423

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.